Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03763643 · ClinicalTrials.gov registry record · Early Phase 1
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
A Early Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT03763643 is a Early Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 21 participants.
The verdict
NCT03763643, a Early Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.
Interventions
- DRUG Rituximab
- PROCEDURE Plasmapheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2025-02-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03763643
The ClinicalTrials.gov registry entry for NCT03763643 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT03763643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03763643 about?
NCT03763643 is a clinical study titled "PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant". This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.
What is the current status of trial NCT03763643?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2019-07-01. Estimated completion is 2025-02-07.
What interventions are being tested in trial NCT03763643?
The interventions under investigation include: Rituximab (DRUG), Plasmapheresis (PROCEDURE).
Who is sponsoring clinical trial NCT03763643?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.